

U.S. Centers for Disease Control and Prevention
National Center for Immunization and Respiratory Diseases

2024-25 Influenza Season Update and Seasonal Influenza Vaccine Recommendations for the 2025-26 U.S. Influenza Season


Dr. Vivien Dugan
Influenza Division, CDC/NCIRD

June 26, 2025



Overview

- 2024-25 influenza season summary
- Proposed updates to the seasonal influenza vaccine recommendations for the 2025-26 influenza season including the following recent FDA approvals:
 - Influenza vaccine composition for the 2025-26 season
 - FluMist (live attenuated influenza vaccine, trivalent) for self- or caregiver administration
 - Change in age indication for Flublok (recombinant influenza vaccine, trivalent) from ≥ 18 years to ≥ 9 years



2024-25 Influenza Season





2024-25 U.S. Influenza Season

- High severity season overall and for all age groups
 - First high severity season since 2017-2018
- Highest cumulative influenza-associated hospitalization rate since 2010-2011
 - October 1, 2024 through April 30, 2025: 128.1 per 100,000
 - Cumulative rate was 102.9 per 100,000 for the severe 2017-18 season
- As of June 7, 246 influenza-associated pediatric deaths have been reported this season


Influenza-Associated Hospitalizations, FluSurv-NET, 2024-2025 Season

- Lab-confirmed influenza-associated hospitalizations in select counties in 14 states
- Approx. 9% of U.S. population
- As of May 17, cumulative rate of 128.1 per 100,000
 - Was 102.9 for 2017-18
- Approx 16% of hospitalized patients required ICU admission and 6% required invasive mechanical ventilation



Influenza-Associated Pediatric Mortality, 2024-2025 Season*

- Death in a person <18 yrs of age
 - with clinically compatible illness
 - and influenza positive laboratory test
 - and no period of complete recovery between illness and death
- Nationally notifiable since 2004
- 246 deaths reported*
- All age groups affected
 - 0-5 months: 7%
 - 6-23 months: 13%
 - 2-4 years: 18%
 - 5-11 years: 37%
 - 12-17 years: 26%



* Through June 7, 2025

<https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html>

Influenza-Associated Pediatric Mortality, 2024-2025 Season*

- Among 246 influenza-associated pediatric deaths reported thus far for 2024-25*,
 - 42% had no known high risk underlying medical condition
 - 40% had a bacterial co-infection of a sterile site
 - 89% of those eligible for influenza vaccination were not fully vaccinated
 - Compared with 82% for the 2023-24 season
- Highest number of pediatric deaths reported in any non-pandemic influenza season since condition became reportable in 2004


2025-26 Seasonal Influenza Vaccine Recommendations

Seasonal Influenza Vaccine Recommendations, 2025-26

- Annual influenza vaccination remains recommended for those aged ≥ 6 months who do not have contraindications
- As previously,
 - No preferential recommendations are made with the exception that high-dose inactivated, recombinant, and adjuvanted inactivated influenza vaccines are preferentially recommended for persons aged ≥ 65 years when available
 - Recipients should receive an age-appropriate influenza vaccine (one approved for their age), with the exception that solid organ transplant recipients aged ≥ 18 years who are taking immunosuppressive medications regimens may receive either high-dose or adjuvanted inactivated vaccines (without preference over other appropriate influenza vaccines)
- Recommendations concerning timing, vaccine selection, and contraindications and precautions remain the same as previously

Recommendations for 2025-26: Updates

- The 2025-26 recommendations include three updates, all of which reflect recent FDA approvals:
 - Influenza vaccine composition for the 2025-26 season
 - FluMist (live attenuated influenza vaccine, trivalent; LAIV₃) for self- or caregiver administration
 - Change in age indication for Flublok (recombinant influenza vaccine, trivalent; RIV₃) from ≥ 18 years to ≥ 9 years



U.S. Influenza Vaccine Composition for the 2025-26 Influenza Season

- All influenza vaccines marketed in the United States for the 2025-26 season will be trivalent
- U.S. influenza vaccine composition for 2025-26 includes an update to the influenza A(H3N2) component:
 - An A/Victoria/4897/2022 (H1N1)pdm09-like virus for egg-based vaccines or an A/Wisconsin/67/2022 (H1N1)pdm09-like virus for cell and recombinant vaccines;
 - An A/Croatia/Y10136RV/2023 (H3N2)-like virus for egg-based vaccines or an A/District of Columbia/27/2023 (H3N2)-like virus for cell and recombinant vaccines;
 - A B/Austria/1359417/2021 (B/Victoria lineage)-like virus

FluMist (LAIV₃) for Self- or Caregiver Administration

- Approved by FDA in September 2024¹; presented to ACIP in April 2025
- Anticipated to be available for the 2025-26 influenza season
- Consumers will be able to order FluMist for delivery for eligible recipients
 - Screening for eligibility performed by central pharmacy, based on ACIP criteria
 - Approved for self-administration for persons aged ≥18 years, or by a caregiver aged ≥18 years for recipients aged 2 through 17 years
- LAIV₃ will continue to be available for administration by healthcare providers as previously
- No changes made to recommendations regarding appropriate populations, contraindications, or precautions

1. <https://www.fda.gov/vaccines-blood-biologics/vaccines/flumist>

Approval of Flublok (RIV₃) for Persons Aged 9 through 17 Years

- Approved by FDA in March 2025¹
- Previously approved for ≥ 18 years; new age indication is ≥ 9 years
- Information has been updated in the Table of available U.S. influenza vaccines for 2025-26



1. <https://www.fda.gov/vaccines-blood-biologics/vaccines/flublok>

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

